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Abstract
Background Cachexia frequently occurs in women with advanced ovarian cancer (OC), along with enhanced inﬂammation.
Despite being responsible for one third of all cancer deaths, cachexia is generally under-studied in OC due to a limited number
of pre-clinical animal models. We aimed to address this gap by characterizing the cachectic phenotype in a mouse model of OC.
Methods Nod SCID gamma mice (n = 6–10) were injected intraperitoneally with 1 × 107 ES-2 human OC cells to mimic dis-
seminated abdominal disease. Muscle size and strength, as well as bone morphometry, were assessed. Tumour-derived effects
on muscle ﬁbres were investigated in C2C12 myotube cultures. IL-6 levels were detected in serum and ascites from tumour
hosts, as well as in tumour sections.
Results In about 2 weeks, ES-2 cells developed abdominal tumours inﬁltrating omentum, mesentery, and adjacent organs.
The ES-2 tumours caused severe cachexia with marked loss of body weight (–12%, P < 0.01) and ascites accumulation in
the peritoneal cavity (4.7 ± 1.5 mL). Skeletal muscles appeared markedly smaller in the tumour-bearing mice (approximately
–35%, P < 0.001). Muscle loss was accompanied by ﬁbre atrophy, consistent with reduced muscle cross-sectional area (–34%,
P < 0.01) and muscle weakness (–50%, P < 0.001). Body composition assessment by dual-energy X-ray absorptiometry
revealed decreased bone mineral density (–8%, P < 0.01) and bone mineral content (–19%, P < 0.01), also consistent with
reduced trabecular bone in both femurs and vertebrae, as suggested by micro-CT imaging of bone morphometry. In the
ES-2 mouse model, cachexia was also associated with high tumour-derived IL-6 levels in plasma and ascites (26.3 and
279.6 pg/mL, respectively) and with elevated phospho-STAT3 (+274%, P < 0.001), reduced phospho-AKT (–44%, P < 0.001)
and decreased mitochondrial proteins, as well as with increased protein ubiquitination (+42%, P < 0.001) and expression of
ubiquitin ligases in the skeletal muscle of tumour hosts. Similarly, ES-2 conditioned medium directly induced ﬁbre atrophy
in C2C12 mouse myotubes (–16%, P < 0.001), consistent with elevated phospho-STAT3 (+1.4-fold, P < 0.001) and altered
mitochondrial homoeostasis and metabolism, while inhibition of the IL-6/STAT3 signalling by means of INCB018424 was
sufﬁcient to restore the myotubes size.
Conclusions Our results suggest that the development of ES-2 OC promotes muscle atrophy in both in vivo and in vitro
conditions, accompanied by loss of bone mass, enhanced muscle protein catabolism, abnormal mitochondrial homoeostasis,
and elevated IL-6 levels. Therefore, this represents an appropriate model for the study of OC cachexia. Our model will aid in
identifying molecular mediators that could be effectively targeted in order to improve muscle wasting associated with OC.
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Introduction
According to the most recent statistics, 22 240 new cases of
ovarian cancer (OC) will be diagnosed by the end of 2018,
and 14 070 women will die from the disease in the USA alone,
thus representing the most lethal among the gynaecologic ma-
lignancies.1 High-grade serous (HGS)-OC accounts for 90% of
the serous carcinomas and two-thirds of all OC deaths.2–5 Early
detection of OC is imperative in order to promote better out-
comes and to prolong the overall survival. Unfortunately, the
symptoms associated with the onset of the disease are often
ambiguous, thereby delaying signiﬁcantly its diagnosis. As a
consequence, only 15% of OCs are currently identiﬁed at a
stage that allows successful treatment. On the contrary, the
majority of OC patients is diagnosed when the disease has al-
ready spread regionally and/or distally, thus signiﬁcantly wors-
ening quality of life and resulting into poorer outcomes.6,7
Current treatment strategies for advanced OCs consist of ag-
gressive surgery aimed at removing the majority of the tumour
followed by intraperitoneal chemotherapy with platinum and a
taxane, such as taxol. Unfortunately, after an initial positive re-
sponse, in most cases, the disease recurs due to development
of chemoresistance and an aggressive disease course that is
often accompanied by the formation of ascites.8–10 This disease
progression is particularly evident in advanced HGS-OCs and is
often associated with hyper-activation of the pro-inﬂammatory
IL-6/STAT3 signalling pathway.3,2,11 IL-6 seems to play a critical
role in OC. Indeed, IL-6 contributes to the occurrence of
paraneoplastic thrombocytosis, a condition that promotes
tumour growth, while its inhibition indirectly slows down
tumour progression.12 High IL-6 levels in ascites and plasma
also associates with shorter survival.12,13
Evidence from our group suggests that activation of the IL-
6/STAT3 pathway also plays a causative role in the pathogen-
esis of cancer cachexia, one of the most distressing complica-
tions associated with the development of OC.14,15 Indeed,
cachexia usually accompanies the development of ascites
and chemoresistance in the most advanced stages of the
disease.16 The majority of advanced OC patients develops
cachexia, which is a major contributor of morbidity and
mortality in these patients. Cachexia is primarily responsible
for body and muscle weight loss and correlates with tumour
burden, increased pro-inﬂammatory cytokine levels, fatigue,
and reduced response to chemo-therapy and radio-
therapy.17–19 Patients presenting with advanced stage OC
often show large tumour and ascites burden that, in turn, re-
sults into severe malnourishment because of decreased oral
intake and compromised bowel functions. As a consequence,
malnutrition and weight loss are frequently diagnosed and
together contribute to substantial impairment of anti-cancer
treatments and poorer prognosis.20–22 Notably, evidence
from ours and other groups also suggests that anti-cancer
therapies play a pivotal role in causing the development of
muscle loss and muscle weakness.23,24 Indeed, chemotherapy
itself is frequently accompanied by nausea, diarrhoea, an-
orexia, and fatigue. Cancer patients affected by muscle deple-
tion show increased drug-related toxicity and reduced
survival that are associated with increased levels of pro-
inﬂammatory cytokines, and these features have been previ-
ously implicated in the occurrence of cachexia.25–29,14
Despite its signiﬁcant negative impact on quality of life, no
effective treatment is currently available for OC-related ca-
chexia. Research related to this ﬁeld remains inadequate, par-
ticularly because of the limited availability of optimal pre-
clinical models that are characterized for muscle and bone
phenotype or function. Indeed, only one OC xenograft, the
mouse bearing the TOV-21G clear cell carcinoma, has been
previously described and partially characterized for the
cancer-associated effects on skeletal muscle.30 While ascites
and bloating are primarily used to diagnose OC, these features
can mask the underlying sarcopenia and delay the diagnosis of
the disease, thus also affecting the overall outcomes.31,32 In-
deed, muscle loss and low skeletal muscle attenuation are of-
ten detected in women undergoing primary debulking surgery
for the treatment of OCs. Along the same line, recent evi-
dence suggests that baseline sarcopenia represents one of
the most accurate prognostic factors for survival in advanced
OC and during chemotherapy treatment.16,33–35
In the present study, we sought to establish and fully charac-
terize the muscle effects associated with the growth of the ES-2
human OC in mice. In vivo growth of the ES-2 cancer cells has
been recently reclassiﬁed as a suitable model for the study of
HGS-OC, based on cell copy number alterations, TP53 muta-
tions, and low frequency of somatic mutations in protein-
coding regions.5,4 In our model, in vivo growth of the ES-2 can-
cer cells induced profound body wasting, associated with mus-
cle, fat, and trabecular bone depletion, which is also consistent
with signiﬁcant loss of muscle strength. The pro-inﬂammatory
cytokine IL-6, along with the activation of the downstream
STAT3-dependent pathway, was associated with the occur-
rence of muscle wasting in in vivo and in vitro conditions. STAT3
blockade by administration of INCB018424 JAK1/2 pharmaco-
logic inhibitor36,15 was shown to prevent myoﬁbre atrophy in
C2C12 cultures exposed to ES-2 conditionedmedium (CM). Fur-
ther, similar to what shown in other routinely used experimen-
tal models of cancer cachexia, the development of OC resulted
in altered activation of regulators of muscle size and markedly
exacerbated protein catabolism, thus representing an ideal
model for the study of OC-associated cachexia.
Methods
Cell cultures
Human ES-2 cells were purchased from ATCC (Manassas, VA,
USA; #CRL-1978) and were cultured in McCoy’s medium
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supplied with 10% foetal bovine serum, 1% glutamine, 1% so-
dium pyruvate, 1% penicillin/streptomycin, in a 5% CO2, 37°C
humidiﬁed incubator. Murine C2C12 skeletal myoblasts
(ATCC) were grown in high glucose Dulbecco’s modiﬁed Ea-
gle’s medium (DMEM) supplemented with 10% foetal bovine
serum, 100 U/mL penicillin, 100 mg/mL streptomycin,
100 mg/mL sodium pyruvate, and 2 mM L-glutamine and
maintained at 37°C in 5% CO2. Myotubes were generated
by exposing the myoblasts to DMEM containing 2% horse
serum and replacing the medium every other day for 5 days.
In order to determine the effects of tumor-derived mediators
on ﬁbre size, myotubes were exposed to 25% or 50% CM,
collected from conﬂuent ES-2 culture plates and subjected
to centrifugation to remove cell debris. The JAK1/2 pharma-
cologic inhibitor INCB018424 (EMD Millipore, Burlington,
MA, USA) was dissolved in sterile Dimethyl sulfoxide (DMSO)
and administered in the culture medium at 400 nM ﬁnal
concentration for up to 48 h, as previously shown.15
Animals
All animal studies were approved by the Institutional Animal
Care and Use Committee at Indiana University School of
Medicine and were in compliance with the National Institutes
of Health Guidelines for Use and care of Laboratory Animals
and with the 1964 Declaration of Helsinki and its later
amendments. Female Nod SCID gamma (NSG) (NOD-scid/
IL2Rgnull) immunodeﬁcient mice (In Vivo Therapeutics Core
Facility, IU Simon Cancer Center, Indianapolis, IN, USA) were
used and housed in a pathogen-free facility at IU LARC (up
to 5 per cage). For the experiments described, animals were
randomized into Controls (n = 6) and ES-2 hosts (n = 10), iden-
tiﬁed with a code, and the investigators were blinded during
allocation, animal handling, and endpoint measurements.
1 × 107 ES-2 cells were inoculated intraperitoneally (i.p.) in
sterile saline.37 The animals were weighed daily. At time of
sacriﬁce, several tissues, including skeletal muscles, were col-
lected, weighed, frozen in liquid nitrogen, and stored at
80°C for further analyses. The tibialis anterior muscle was
mounted in OCT and frozen in N2-cooled isopentane for his-
tology, as previously described.38 The mouse carcasses were
ﬁxed for 2 days in 10% neutral buffered formalin and then
transferred into 70% ethanol for storage of bone tissues.
Grip strength
The evaluation of the whole body strength in mice was
assessed as described in Bonetto et al.39 The absolute grip
strength (peak force, expressed in grams) was recorded by
means of a grip strength metre (Columbus Instruments, Co-
lumbus, OH, USA). Five measurements were completed, and
the top three measurements were included in the analysis.
In order to avoid habituation, the animals were tested for
grip strength up to once per week.
Assessment of muscle cross-sectional area
For histology and morphometry of skeletal muscle, 8 μm
thick cryosections of tibialis anterior muscles taken at the
mid-belly region were stained with haematoxylin and eosin
as reported in Bonetto et al.39 All samples were observed
under an Axio Observer.Z1 motorized microscope (Zeiss,
Oberchoken, Germany), and images were recorded for
morphometric examination. For the analysis of the cross-
sectional area, muscle ﬁbres (n = 300–500 per sample) were
measured using a Cintiq pen tablet input device (Wacom,
Vancouver, WA, USA) and ImageJ 1.43 software,40 as also
described in Bonetto et al.39
Assessment of myotube size
Cell layers were ﬁxed in ice-cold acetone–methanol and incu-
bated with an anti-Myosin Heavy Chain antibody (MF-20,
1:200; Developmental Studies Hybridoma Bank, Iowa City,
IA, USA) and an AlexaFluor 488-labelled secondary antibody
(Invitrogen, Grand Island, NY, USA). Analysis of myotube size
was performed by measuring the average diameter of long,
multi-nucleate ﬁbres (n = 250–350 per condition) avoiding
regions of clustered nuclei on a calibrated image using the
ImageJ 1.43 software.40
Immunohistochemistry of tumour tissue
For morphological and immunohistochemical analysis of OC
tissue, parafﬁn-embedded ovarian abdominal tumours
10 μm thick sections were generated. Deparafﬁnization of
the slides was performed through a series of incubations in
xylene, 100% ethanol, 95% ethanol, 70% ethanol, and deion-
ized water. Antigen retrieval was performed by treatment in
10 mM citrate buffer solution for 30 min at sub-boiling tem-
perature. Endogenous peroxidase activity was inhibited by a
10 min incubation in 3% H2O2. Sections were subsequently
blocked in Tris-buffered saline (TBS)-Tween buffer containing
5% goat serum for 1 h at room temperature. A primary rabbit
anti-IL-6 antibody (#208113; Abcam, Cambridge, MA, USA)
was added (1:50) and incubated overnight in a humidiﬁed
box at 4°C. Normal rabbit IgG were used as negative
controls. Sections were then incubated with the ‘EnVision+
System-HRP-labelled polymer secondary antibody’ (DAKO,
Carpinteria, CA, USA) for 1 h at room temperature. The reac-
tion was then visualized with the DAKO ‘Liquid DAB+sub-
bstrate chromogen system’ according to the manufacturer’s
instructions. Slides were counterstained with Harrys
Haematoxylin (1:1 in deionized water) for up to 5 min,
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dehydrated with incubations in 70% ethanol, 95% ethanol,
100% ethanol, and xylene, and mounted with xylene-based
Cytoseal XYL mounting medium (Thermo Fisher Scientiﬁc,
Suwanee, GA, USA).
MitoTracker staining
The mitochondria polarization was determined using
the MitoTracker Red CMXRos selective probe (#M7512,
Invitrogen, Carlsbad, CA, USA). C2C12 myotubes were ex-
posed to unconditioned medium (UCM) or ES-2 CM for up
to 48 h and subsequently incubated in serum-free medium
containing 100 nM MitoTracker at 37°C for 30 min. The cells
were then washed with Phosphate-buffered saline (PBS) and
ﬁxed with 3.7% formaldehyde in serum-free medium at 37°C
for 15 min. 40,6-diamidino-2-phenylindole (DAPI) staining was
then performed to stain the nuclei. Images were captured
using an Axio Observer.Z1 motorized microscope (Zeiss).
Quantitative measurement of red ﬂuorescence intensity
was analysed using the ImageJ 1.43 software.40
Body composition assessment by dual-energy X-ray
absorptiometry
Lean and adipose tissue, as well as whole body bone mineral
density (BMD) and bone mineral content (BMC) were assessed
by means of dual-energy X-ray absorptiometry (DXA) scanning
of formalin-ﬁxed carcasses. According to the manufacturer’s
guidelines, in order to calibrate and validate the apparatus
for its performance, a spine phantom was scanned using the
Lunar PIXImus densitometer (PIXImus, Fitchburg, WI, USA)
before scanning the ﬁrst carcass. Animal carcasses were
placed in a prone position with the limbs outstretched. From
the whole-body scans, areal BMD and BMC were calculated
for the entire body minus head region of interest (ROI).
Microcomputed tomography analysis of femurs
and vertebrae bone morphometry
Microcomputed tomography (μCT) scanning was performed
to measure morphological indices of metaphyseal regions of
femurs and vertebrae, as described in Bouxsein et al.41 After
euthanasia, the mouse carcasses were ﬁxed for 2 days in 10%
neutral buffered formalin, transferred into 70% ethanol, the
right femurs and the ﬁfth lumbar vertebrae dissected, and
prepared for μCT scanning on a high-throughput μCT speci-
men scanner. Bone samples were rotated around their long
axes, and images were acquired using a Bruker Skyscan
1176 (Bruker, Kontich, Belgium) with the following parame-
ters: pixel size = 9 μm3; peak tube potential = 50 kV; X-ray
intensity = 500 μA; 0.9° rotation step. Raw images were re-
constructed using SkyScan reconstruction software (NRecon;
Bruker) to three-dimensional cross-sectional image data sets
using a three-dimensional cone beam algorithm. Structural
indices were calculated on reconstructed images using the
SkyScan CT Analyser software (CTAn; Bruker). Cortical and
trabecular bone were separated using a custom processing
algorithm in CTAn, based on the different thicknesses of the
structures. Cortical bone was analysed by threshold 160–
255 in the femoral mid-shaft. Cortical bone parameters
included bone volume fraction (Ct.BV/TV), thickness (Ct.Th),
and porosity. Trabecular bone was analysed between 2.0
and 3.0 mm under the femoral distal growth plate and
1 mm equally between the distal and proximal growth plates
in the ﬁfth lumbar vertebra using a threshold of 80–255.
Trabecular parameters included bone volume fraction
(Tb.BV/TV), number (Tb.N), thickness (Tb.Th), separation
(Tb.Sp), and connectivity (Conn.Dn).
Western blotting
Total protein extracts were obtained by lysing cell layers or
homogenizing 100 mg quadriceps muscle tissue in
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl,
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), and 50 mM Tris, pH 8.0) completed with prote-
ase (Roche, Indianapolis, IN, USA) and phosphatase (Thermo
Scientiﬁc, Rockford, IL, USA) inhibitor cocktails. Cell debris
were removed by centrifugation (15 min, 14 000 g), and the
supernatant was collected and stored at 80°C. Protein con-
centration was determined using the bicinchoninic acid (BCA)
protein assay method (Thermo Scientiﬁc). Protein extracts
(30 μg) were then electrophoresed in 4–15% gradient SDS
Criterion TGX precast gels (Bio-Rad, Hercules, CA, USA). Gels
were transferred to nitrocellulose membranes (Bio-Rad).
Membranes were blocked with SEA BLOCK blocking reagent
(Thermo Scientiﬁc) at room temperature for 1 h, followed
by an overnight incubation with diluted antibody in SEA
BLOCK buffer containing 0.2% Tween-20 at 4°C with gentle
shaking. After washing with PBS containing 0.2% Tween-20,
the membrane was incubated at room temperature for 1 h
with either Anti-rabbit IgG (H + L) DyLight 800 or Anti-mouse
IgG (H + L) DyLight 600 (Cell Signaling Technologies, Danvers,
MA, USA). Blots were then visualized with Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Opti-
cal density measurements were taken using the Gel-Pro
Analyser software. Antibodies used were pSTAT3-Y705
(#9145), STAT3 (#8768), p-Akt-S473 (#4060), Akt (#9272), p-
P38 MAPK (T180/Y182) (#4511), P38 MAPK (#9212), p-
ERK1/2 (p-p44/42 MAPK, T202/Y204) (#4370), ERK1/2 (p44/
42 MAPK) (#4695), OPA1 (#80471), Mitofusin-2 (#9482),
DRP1 (#8570), Cytochrome C (#11940), and Ubiquitin
(#3933) from Cell Signaling Technologies, PGC1α (#ab3242)
from Abcam, and α-Tubulin (#12G10) from Developmental
Studies Hybridoma Bank.
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Masson trichrome staining
For direct visualization of collagen and histological assess-
ment of collagen deposition, trichrome staining was per-
formed on tibialis anterior muscle sections using the
Masson Trichrome Staining Kit (Richard-Allan Scientiﬁc, San
Diego, CA, USA) and according to the instructions provided
by the manufacturer. Brieﬂy, 8 μm thick muscle sections were
ﬁxed in 10% neutral buffered formalin for 1 h at room tem-
perature. The sections were then re-ﬁxed in Bouins solution
for overnight at room temperature and then stained with
Weigerts Haematoxylin (for nuclei staining), followed by
Biebrich Scarlet-Acid Fuchsin (for cytoplasm staining) and Al-
anine blue (for collagen staining). Samples were then
dehydrated and observed under an Axio Observer.Z1 motor-
ized microscope (Zeiss).
Succinate dehydrogenase staining
Tibialis anterior cross sections (10 μm) were cut on a cryostat
and incubated for 40 min at 37°C with 0.5 mg/mL nitroblue
tetrazoliumand, 50 mM Na-succinate, and 0.08 mM phena-
zine methosulfate in PBS. The slide was then incubated in ac-
etone, rinsed in deionized water, mounted with PBS-glycerol,
and photographed. The ratio between oxidative [succinate
dehydrogenase (SDH)-positive, dark purple] and glycolytic
(SDH-negative, light purple) ﬁbres (expressed as percentage
of the total ﬁbres) was determined using the ImageJ software
on randomly chosen ﬁelds (n = 100–150 ﬁbres).
Succinate dehydrogenase enzymatic activity
The total SDH enzymatic activity was measured using a SDH
Colorimetric Assay Kit (#MAK197; Sigma-Aldrich, St. Louis,
MO, USA), as per manufacturer’s instruction. Brieﬂy, 10 mg
of quadriceps muscle tissue were homogenized in 100 μL
ice-cold assay buffer and subsequently centrifuged. The su-
pernatant was collected, and the total protein content was
measured using the BCA protein assay (Thermo Fisher Scien-
tiﬁc, Waltham, MA, USA). Ten microlitres of homogenate
were then added to a 96-well plate, along with an appropri-
ate volume of reaction mix, and then incubated at 37°C.
The absorbance at 600 nm was measured after 0, 3, and
20 min. The rate of absorbance decrease between 3 and
20 min was corrected for the protein concentration and used
to calculate the SDH content.
Extracellular ﬂux analysis
The mitochondrial oxygen consumption rate (OCR) was mea-
sured using a Mito-Stress Test kit in a Seahorse XF Extracellu-
lar Flux Analyser (Agilent, Santa Clara, CA, USA), according to
the manufacturer’s instructions. C2C12 myoblasts were
plated in an XF cell culture microplate (30 000 cells/cm2)
and then differentiated to myotubes by exposing the myo-
blasts to DMEM containing 2% horse serum and replacing
the medium every other day for 5 days. The cells were then
exposed to UCM or 50% ES-2 CM for up to 48 h. Prior to
the assay, the cells were incubated in Seahorse XF Base
Medium containing 1 mM Na-Pyruvate, 2 mM glutamine, and
25 mM glucose in a non-CO2 incubator for 1 h at 37°C. Basal
respiration was monitored prior to the addition of 2 μM
oligomycin. The OCR values were obtained at baseline and after
the addition of 2 μM oligomycin, 1 μM carbonyl cyanide-
4(triﬂuoromethoxy)phenylhydrazone (FCCP), and 0.5 μM Rote-
none. OCR was automatically calculated and recorded by the
Seahorse XF software, and data were expressed as pmol/min.
Real-time quantitative polymerase chain reaction
RNA from quadriceps was isolated using the miRNeasy Mini
kit (Qiagen, Valencia, CA, USA) and following the protocol pro-
vided by the manufacturer. RNA was quantiﬁed by using a
Synergy H1 spectrophotometer (BioTek, Winooski, VT, USA).
RNA integrity was checked by electrophoresis on 1.2% aga-
rose gel containing 0.02 mol/L morpholinopropanesulfonic
acid and 18% formaldehyde. Total RNA was reverse
transcribed to cDNA by using the Verso cDNA kit (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Transcript levels were
measured by Real-Time PCR (Light Cycler 96, Roche) taking
advantage of the TaqMan gene expression assay system
(Life Technologies, Carlsbad, CA, USA). Expression levels for
Atrogin-1 (Mm00499523_m1), MuRF-1 (Mm01185221_m1),
Fbxo21 (SMART; Mm01208074_m1), and Fbxo31
(Mm00505343_m1) were detected. Gene expression was nor-
malized to TATA-binding protein (TBP) (Mm01277042_m1)
levels using the standard 2ΔCT methods.
Quantiﬁcation of IL-6 in plasma and ascites
The circulating levels of human IL-6 were measured in mouse
poor-platelet plasma and ascites from control and ES-2 bear-
ing mice by using a speciﬁc enzyme-linked immunosorbent
assay (ELISA) kit (#D6050; Bio-Techne Corporation, Minneap-
olis, MN, USA), according to the manufacturer’s protocol.
Statistical analysis
Results are presented as means ± standard deviation. Signiﬁ-
cance of the differences was determined by either unpaired
t-test or analysis of variance followed by Tukey’s post-test.
Differences were considered signiﬁcant when P < 0.05.
ES-2 cells cause cachexia in vivo 5
Journal of Cachexia, Sarcopenia and Muscle 2018
DOI: 10.1002/jcsm.12311
Results
The ES-2 tumours cause signiﬁcant body and
muscle weight loss
In order to assess the effects of OC development on skeletal
muscle mass in in vivo conditions, NSG female mice were in-
traperitoneally injected with 1 × 107 ES-2 cells.4 Both control
and tumour hosts were assessed for changes in body weight
over the duration of the entire experiment. After an initial lag
phase, the ES-2-bearing mice displayed signiﬁcant accumula-
tion of ascites, consistent with increased body weight com-
pared with the control animals (4.7 ± 1.5 mL) (Figure 1A). In
line with previous data, the ascites was highly cellular and
milky in appearance, with tumour cells existing mostly as
single-cell suspension and with limited inﬁltration into dia-
phragm, pancreas (Figure S1), mesentery, or omentum to
form solid tumours.37 However, the tumour-free body weight
was signiﬁcantly decreased in the tumour hosts (12% vs.
Control, P < 0.01) (Figure 1B). Additionally, skeletal muscles
were markedly impacted by tumour growth, with the quadri-
ceps showing a 38% reduction in weight with respect to the
Controls (P < 0.001). Similarly, the heart was markedly
smaller in the tumour hosts (35% vs. Control, P < 0.001)
(Figure 2). The liver was also affected by the growth of the
ES-2 tumours (28%, P < 0.01), while the spleen was un-
changed compared with the control animals (Figure 3). Nota-
bly, the gonadal adipose tissue was massively depleted in the
tumour hosts (P < 0.001), therefore suggesting the occur-
rence of severe tumour-associated wasting (Figure 3).
Ovarian cancer growth affects muscle size and
function
Along with the depletion of skeletal muscle mass, the growth
of the ES-2 OC cells was associated with the occurrence of se-
vere muscle atrophy (34% vs. Control, P < 0.01) (Figure
4A). No other apparent changes in muscle histology, including
ﬁbrosis, were detected (Figure S2A). Similarly, the number of
central nuclei was comparable between control and tumour
hosts, thus suggesting the absence of muscle regeneration
(Figure S2B). Consistent with the reduced ﬁbre size, progres-
sive loss of muscle strength was observed over the experi-
mental period, and severe muscle weakness was apparent
at time of sacriﬁce (50% vs. Control, P < 0.001) (Figure 4B).
Figure 1 The ES-2 tumours cause signiﬁcant body weight (BW) loss. Body weight curves (A) and body weight change (i.e. body weight at time of sac-
riﬁce vs. initial body weight) (B) in mice bearing the ES-2 ovarian cancer (n = 6–10). Data expressed as means ± standard deviation. Signiﬁcance of the
differences: ***P < 0.001 vs. Control.
Figure 2 Growth of the ES-2 ovarian cancer causes marked muscle depletion. Muscle weights in ES-2 tumour hosts (n = 6–10). Weights were normal-
ized to the initial body weight (IBW) and expressed as weight/100 mg IBW. Data expressed as means ± standard deviation. Signiﬁcance of the differ-
ences: ***P < 0.001 vs. Control.
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The growth of the ES-2 tumour affects the overall
body composition
In order to understand the effects of ES-2 tumour develop-
ment on body composition, the carcasses from both control
and tumour-bearing animals were assessed by means of
DXA. The amount of total fat and lean tissue was signiﬁcantly
reduced in the tumour hosts (12% and 23% vs. Control,
respectively) (Figure 5). Interestingly, the bone tissue was af-
fected by ES-2 growth, with BMD and BMC signiﬁcantly
decreased with respect to the control animals (8% and
19%, respectively) (Figure 5).
Ovarian cancer promotes the loss of trabecular
bone
In order to determine whether the reduction in BMC and
BMD was also consistent with loss of bone mass, morphom-
etry of sections from femurs and vertebrae extracted from
Figure 3 Organ size is affected by the occurrence of ES-2 ovarian cancer. Liver, spleen, and gonadal fat weights in mice bearing the ES-2 ovarian cancer
(n = 6–10). Weights were normalized to the initial body weight (IBW) and expressed as weight/100 mg IBW. Data expressed as means ± standard de-
viation. Signiﬁcance of the differences: **P < 0.01, ***P < 0.001 vs. Control.
Figure 4 Development of ovarian cancer is accompanied by muscle atrophy and progressive muscle weakness. Muscle morphology (haematoxylin and
eosin staining) and quantiﬁcation of the cross-sectional area (CSA) in the tibialis anterior muscle of ES-2 hosts. Scale bar: 100 μm (A). Whole body grip
strength in animals bearing the ES-2 tumours, reported as peak force, was measured weekly by taking advantage of a grip strength metre and
expressed as the average of the three top pulls from each animal (n = 6–10) (B). Data expressed as means ± standard deviation. Signiﬁcance of the
differences: **P < 0.01, ***P < 0.001 vs. Control.
Figure 5 Body composition is affected by the growth of ES-2 tumours. Body composition was assessed by means of dual-energy X-ray absorptiometry
scanning of carcasses from ovarian cancer hosts (n = 6–10). Fat and lean tissue, total bone mineral density (BMD), and bone mineral content (BMC)
measurements of the whole body are shown. Data (means ± standard deviation) are expressed as g (for fat, lean, and BMC) or g/cm2 (for BMD).
Signiﬁcance of the differences:
*
P < 0.05,
**
P < 0.01,
***
P < 0.001 vs. Control.
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animals bearing OCs was analysed by means of μCT and the
amount of trabecular bone quantiﬁed. The ES-2 tumour hosts
exhibited a severe loss of trabecular bone in the femur
(Figure 6A–B). This was evidenced by markedly reduced tra-
becular bone volume fraction (BV/TV;39%, P< 0.01), thick-
ness (Tb.Th; 16%, P < 0.05), number (Tb.N; 23%,
P < 0.01), and connectivity density (Conn.Dn; 23%,
P < 0.05), as well as increased trabecular separation (Tb.Sp;
+11%, P = 0.10) and pattern factor (Tb.pf; +43%, P < 0.01)
vs. Control (Figure 6A). The vertebral trabecular bone was
also affected by the development of OC, as shown by re-
duced BV/TV (27%, P < 0.001), Tb.Th (15%, P < 0.001),
Tb.N (14%; P < 0.01), and Conn.Dn (10%, P < 0.001)
and by increased Tb.Sp (+15%, P < 0.001) and Tb.pf (+41%,
P < 0.01) with respect to the control mice (Figure 6B).
Pro-atrophic signalling pathways are activated in
the muscle of mice bearing ovarian cancer
In order to investigate whether the muscle phenotype ob-
served following ES-2 tumour growth was also associated
with modulation of muscle-speciﬁc signalling pathways, we
assessed the levels of a number of proteins known to be in-
volved in the regulation of skeletal muscle growth. Interest-
ingly, we observed modulation of several mediators of
muscle atrophy and markers of mitochondrial biogenesis
using western blotting analysis performed on whole muscle
protein extracts from mice bearing OC. In particular, the tu-
mour hosts showed increased phospho-STAT3/STAT3 ratio
(+274% vs. Control, P < 0.001) and decreased activation of
AKT1/2 (44% vs. Control, P < 0.001), in line with previous
data generated in animal models characterized by muscle at-
rophy42,15 (Figure 7A). As expected, expression of total STAT3
was also increased (+71% vs. Control, P < 0.001), in accor-
dance with published evidence from our laboratory.14 The
growth of the ES-2 tumour was also associated with in-
creased phospho-P38 (+156% vs. Control, P < 0.05) and un-
changed phospho-ERK1/2 levels (Figure 7A). Interestingly,
mitochondrial proteins, such as OPA1 (78%, P < 0.001),
Mitofusin-2 (40%, P < 0.05), PGC1α (79%, P < 0.001),
and Cytochrome C (78%, P < 0.001), were also markedly
decreased in the muscle of the ES-2 hosts compared with
the control animals, thereby suggesting that mitochondrial al-
terations may play a role in the development of muscle
wasting and muscle weakness (Figure 7B). Accordingly,
myoﬁbre oxidative capacity was signiﬁcantly reduced in the
skeletal muscle of ES-2 hosts, as conﬁrmed by the analysis
of the SDH enzymatic activity (Figure 7C). In a similar manner,
based on the quantiﬁcation of the muscle SDH staining con-
ducted in the tibialis muscle of ES-2 bearing mice (Figure
7D), HGS-OC growth was also shown to drive an oxidative-
to-glycolytic ﬁbre shift, characterized by a reduction in oxida-
tive ﬁbres (dark purple) and a signiﬁcant increase in the num-
ber of ﬁbres associated with a more glycolytic metabolism
(light purple) (P < 0.001 vs. Control; Figure 7E).
Figure 6 Growth of the ES-2 tumour affects bone quality. Representative three-dimensional rendering of microcomputed tomography scan images
and quantiﬁcation of bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N), and trabec-
ular connectivity density (Conn.Dn) in the femurs (A) and vertebrae (B) of mice bearing the ES-2 tumour (n = 6–10). Data are expressed as means ± stan-
dard deviation. Signiﬁcance of the differences:
*
P < 0.05,
**
P < 0.01,
***
P < 0.001 vs. Control.
8 F. Pin et al.
Journal of Cachexia, Sarcopenia and Muscle 2018
DOI: 10.1002/jcsm.12311
Figure 7 Development of ovarian cancer is accompanied by changes in the expression of key regulators of muscle size. Representative western blot-
ting and quantiﬁcation for pSTAT3, pAKT, pP38, and pERK1/2 (A) and OPA1, Mitofusin-2, PGC1α, and Cytochrome C (Cyt C) (B) in whole muscle protein
extracts from mice bearing ovarian cancers (n = 6–10). Levels of phosphorylated proteins were normalized to the respective total protein expression.
Tubulin was used as loading control. Data are expressed as fold change vs. control and reported as means ± standard deviation. Succinate dehydro-
genase (SDH) enzymatic activity (expressed as mU/μL) in quadriceps muscle from control mice and ES-2 hosts (n = 6–10) (C). Succinate dehydrogenase
staining performed on 8 μm thick sections from tibialis anterior muscles excised from controls and ES-2 (n = 6–10) (D). The number of oxidative (dark
purple) and glycolytic (light purple) ﬁbres was assessed and reported as % of total ﬁbres per ﬁeld (E). Scale bar: 100 μm. Data are expressed as
means ± standard deviation. Signiﬁcance of the differences: *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control.
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Protein catabolism is exacerbated in the muscle of
ES-2 tumour hosts
In order to determine whether protein catabolism was asso-
ciated with the loss of muscle mass in animals bearing OC,
markers of protein catabolism, as well as protein
ubiquitination, were investigated. The total ubiquitination
was more elevated in the muscle of ES-2 hosts (+42% vs. Con-
trol, P < 0.001) (Figure 8A), in line with the overexpression of
the ubiquitin ligases Atrogin-1 (+3.9-fold vs. Control,
P < 0.001), MuRF-1 (+8.4-fold vs. Control, P < 0.001), and
Fbxo31 (+3.0-fold vs. Control, P < 0.001), normally
overexpressed in conditions associated with muscle atrophy,
while Fbxo21 (SMART) was not affected by tumour develop-
ment43,44 (Figure 8B).
The IL-6/STAT3 signalling is associated with muscle
atrophy in the ES-2 model of ovarian cancer
In order to investigate whether cancer cell-derived factors
were directly responsible for muscle wasting, we exposed
C2C12 murine myotubes to ES-2 CM for up to 48 h, while
control cells were exposed to UCM. No effects associated
with the exposure of C2C12 myotubes to McCoys medium
(either 25% or 50% in differentiation medium) were observed
(Figure S3). On the other hand, the ES-2 CM determined
concentration-dependent effects on myotube size (11%
and 16% vs. UCM with 25% and 50% CM, respectively)
(Figure 9A). Notably, the phosphorylation of STAT3, down-
stream of IL-6 binding to its receptor, was signiﬁcantly higher
in the tumour medium-treated C2C12 myotubes compared
Figure 8 Elevated muscle protein catabolism is a hallmark of ovarian cancer cachexia. Representative western blotting and quantiﬁcation for total
ubiquitin (A) in whole muscle protein extracts from mice bearing ovarian cancers (n = 6–10). Tubulin was used as loading control. Gene expression
levels for Atrogin-1, MuRF-1, Fbxo21, and Fbxo31 ubiquitin ligases (B) were performed by quantitative real-time PCR. Gene expression was normalized
to TBP levels. Data (fold change vs. control) were expressed as means ± standard deviation.
Figure 9 ES-2-derived factors directly affect ﬁbre size in C2C12 myotube cultures. Assessment of myoﬁbre size in C2C12 murine myotube cultures
exposed for up to 48 h to 25% and 50% ES-2 unconditioned medium (UCM) or conditioned medium (CM) in 2% horse serum-containing differentiation
medium (n = 250–350). Green staining: myosin heavy chain. Scale bar: 100 μm (A). Representative western blotting for pSTAT3 and STAT3 in whole
protein extracts from C2C12 myotubes exposed to different concentrations of ES-2 CM (n = 3) (B). Representative western blotting and quantiﬁcation
for pSTAT3 (C) and myotubes size (D) in C2C12 myotubes exposed to 50% ES-2 CM, with or without INCB018424 (400 nM). pSTAT3 levels were nor-
malized to STAT3 expression. Tubulin was used as loading control. ND, not detected. Data (means ± standard deviation) are expressed as fold change
vs. UCM. Signiﬁcance of the differences: *P < 0.05, **P < 0.01, ***P < 0.001 vs. UCM; #P < 0.05 vs. CM.
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with the control cells exposed to UCM (+1.4-fold in 25% CM
vs. UCM, P < 0.001) (Figure 9B). In order to understand
whether counteraction of the IL-6/STAT3 signalling was sufﬁ-
cient to preserve the myoﬁbre size in the presence of OC-
derived factors, we exposed C2C12 myotubes to 50% ES-2
CM, with or without INCB018424, a JAK1/2 inhibitor previ-
ously shown to promote body weight gain in patients with
myeloﬁbrosis36 and to preserve ﬁbre size in C2C12 cells ex-
posed to high IL-615 (Figure S4). As shown in Figure 9C,
INCB018424 was sufﬁcient to protect the C2C12 myotubes
from undergoing atrophy in the presence of ES-2 CM, also
consistent with abolished STAT3 phosphorylation (Figure
9D). To further support the idea that activation of the IL-6/
STAT3 pathway plays a pivotal role in determining the ca-
chectic phenotype in the ES-2 model, elevated human IL-6
was detected at high levels in plasma and ascites from ES-2
bearing mice (26.3 and 279.6 pg/mL, respectively) compared
with the control animals (not detected) (Figure 10A), thus
suggesting that the OC tumours were the main source of IL-
6 in this animal model. To further corroborate our ﬁndings,
IL-6 was also found expressed in abdominal solid tumours
collected from OC hosts (Figure 10B).
Mitochondrial homoeostasis and respiration are
impaired in C2C12 myotubes exposed to ES-2
conditioned medium
To assess whether tumour-derived factors were directly re-
sponsible for the changes in the expression of mitochondrial
proteins, as also described in the muscle of OC hosts, C2C12
myotubes were exposed to 25% and 50% CM from ES-2 cul-
tures for up to 48 h. Expression of proteins associated with
mitochondrial biogenesis (PGC1α, Cytochrome C), fusion
(OPA1), and ﬁssion (DRP1) was evaluated by means of west-
ern blotting. Exposure to 50% CM was associated with signif-
icant reduction in PGC1α levels (45% vs. UCM, P < 0.05),
Cytochrome C (46% vs. UCM, P < 0.05), and OPA1 (35%
vs. UCM, P < 0.05), while DRP1 was substantially unchanged
(Figure 11A). Consistently, the amount of polarized mitochon-
dria, as measured by means of MitoTracker staining (Figure
11B), was signiﬁcantly decreased in C2C12 cells exposed to
50% ES-2 CM (50% vs. UCM, P < 0.01). Additionally, the ex-
tracellular ﬂux analysis performed by means of Seahorse XF
(Figure 11C) showed signiﬁcant reduction in mitochondrial
respiration (27% vs. UCM, P < 0.01), spare respiratory ca-
pacity (31% vs. UCM, P < 0.01), and overall ATP production
(25% vs. UCM, P < 0.01). On the contrary, the proton leak
was markedly increased (+214% vs. UCM, P < 0.05).
Discussion
Ovarian cancer is the deadliest amongst gynaecologic malig-
nancies in the USA.1 Advanced OC patients often experience
the symptoms of cachexia, an extremely debilitating condi-
tion mainly responsible for body weight loss, severe muscle
and fat wasting, fatigue, decreased response to antineoplas-
tic therapies, and overall reduced survival.45,46 We and others
showed that counteraction of cachexia by means of pro-
anabolic agents prevents chemotherapy side toxicities in skel-
etal muscle and promotes better survival in cancer hosts, de-
spite limited or no effects on tumour size.47–49,30,24 This also
suggests that preservation of skeletal muscle mass per semay
beneﬁt quality of life and survival in patients with cancer.
Hence, determining the mechanisms responsible for muscle
wasting in OC represents a task of the utmost importance.
Unfortunately, cachexia is not easily detected in women with
OC, due to bulky tumour deposits or to the development of
ascites that could mask changes in body weight.34,50
Research on OC-related cachexia is currently limited by the
paucity of molecular data on the development of cachexia in
the available animal models. These models remain poorly
characterized in terms of body composition as well as cyto-
kine and gene expression data.3 Zhou et al. previously
Figure 10 IL-6 is elevated in ES-2 hosts. IL-6 levels assessed in plasma and ascites from control and ES-2 bearing mice (n = 6–10) by means of ELISA (A).
Ascites was collected at time of euthanasia and subjected to centrifugation to remove cells and cellular debris. Data (pg/mL) are expressed as
means ± standard deviation. Immunohistochemistry for IL-6 in two representative sections from ES-2 solid tumours inﬁltrating murine pancreas
(n = 10) (B). Normal rabbit IgG was used as negative control. Scale bar: 50 μm.
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reported that the growth of the TOV-21G clear cell carci-
noma, a distinct pathologic subtype of epithelial OC, only ac-
counting for less than 5% of all ovarian malignancies,
promotes progressive body and muscle weight loss, although
no functional data were shown.30 Administration of
ACVR2B/Fc was shown to completely restore muscle wasting
in this model.30 ACVR2B/Fc is an inhibitor of the Activin Re-
ceptor 2B signalling known to preserve muscle mass and pro-
long survival in tumour hosts and to increase muscle and
bone mass following chemotherapy treatment.48 However,
based on the results of a recent genomic proﬁling, the TOV-
21G tumours were found to possess few copy number alter-
ations and a ‘hyper-mutated’ genome, thus setting this cell
type apart from the rest of the OC cell lines and from the
HGS-OC tissue samples.4
In order to establish an animal model that resembles the
human phenotype as close as possible, in the present study,
we characterized the pro-cachectic effects associated with
the in vivo growth of ES-2 OC xenografts, both at the func-
tional and molecular level. The ES-2 cells were originally
classiﬁed as ovarian clear cell carcinoma.51 After compari-
son with the genomic proﬁles of the most extensively stud-
ied HGS-OC cell types, such as SK-OV-3, A2780, OVCAR-3,
and CAOV-3, the ES-2 cells were recently classiﬁed as a suit-
able model for the study of HGS-OC, the most aggressive
subtype of OCs, accounting for up to two-thirds of all
deaths among women affected with this kind of
malignancy.4,3
The implantation of OC tumours in immune-deﬁcient ani-
mals is an accepted method to model and study the develop-
ment, the progression, and the response to anti-proliferative
treatments of OC cells, in line with the ﬁrst report describing
the use of xenografts of human tumours.52 However, none of
these models had been previously characterized in terms of
effects on muscle size, muscle function, and bone mass, thus
representing a critical gap to be addressed. In our study, hu-
man ES-2 cells were inoculated intraperitoneally in immune-
deﬁcient mice, similarly to what previously described.51
One of the main limitations associated with the use of
xenograft models relates to the difﬁculty in monitoring intra-
peritoneal disease formation and tumour progression in vivo.
Indeed, in the absence of validated exogenous serum
markers, the assessment of tumour growth, especially at
early time points, is possible only by means of magnetic res-
onance imaging or by using cells that are stably expressing
ﬂuorescent markers, such as green ﬂuorescent protein
(GFP).53 However, these analyses can often be cost-
prohibitive or very stressful for the experimental animals.
An additional limitation is often associated with the site of
tumour implantation, e.g. subcutaneous vs. intraperitoneal
vs. orthotopic. The majority of OC xenograft models de-
scribed in the literature displays subcutaneous or intraperito-
neal implantation of OC cells, while only recently orthotopic
tumour implantation has been reported as a novel approach
that more closely resembles the human disease.54 Some
patient-derived xenograft (PDX) models for the study of OC
are also available that likely recapitulate the primary disease
and the patient phenotype, as well as important features
such as tumour histotype and response to chemotherapy.
However, Ricci et al.55 advised on the difﬁculty in developing
these models, associated with an overall low take rate of
about 25%, and raised concerns about the higher genomic
Figure 11 Mitochondrial homoeostasis and respiration are impaired in C2C12 myotubes exposed to ES-2 conditioned medium (CM). Representative
western blotting and quantiﬁcation for PGC1α, Cytochrome C (Cyt C), OPA1, and DRP1 in protein extracts from C2C12 myotubes exposed to different
concentrations of ES-2 CM (n = 3). Tubulin was used as loading control (A). Mitochondrial polarization assessed by means of MitoTracker red CMXRos
staining in C2C12 exposed to 50% ES-2 CM (n = 3). Red signal intensity was quantiﬁed by using the ImageJ software (ﬁve ﬁelds per sample). Scale bar:
100 μm (B). Basal respiration (BR), mitochondrial respiration (MR), spare respiratory capacity (SRC), proton leak (PL), and ATP production (data
expressed in pmol/min) determined by extracellular ﬂux analysis in C2C12 myotubes exposed to 50% ES-2 CM (n = 3) (C). Data are reported as
means ± standard deviation. Signiﬁcance of the differences: *P < 0.05, **P < 0.01, ***P < 0.001 vs. unconditioned medium (UCM).
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variability found in the PDX models compared with patient
tumours. Moreover, these PDX models have not been investi-
gated for cachexia development.
Importantly, it is well accepted that the intraperitoneal im-
plantation of ovarian tumours is generally an appropriate and
clinically relevant way to model the development and the
progression of OC.56 In our experimental approach, we chose
to implant ES-2 cells intraperitoneally in order to simulate
disseminated abdominal disease and ascites formation, as
frequently observed in women with advanced HGS-OC. Our
choice was also supported by the evidence that the ES-2 tu-
mours were shown to maintain similar undifferentiated phe-
notype and proliferative rates, regardless of the injection
site.37 In the present study, we found that approximately
2 weeks after tumour inoculation, the NSG mice demon-
strated signiﬁcant ascites accumulation, along with severe
muscle weight loss and increased muscle weakness. These
features are consistent with advanced disease in patients
with OC and are normally referred to as cancer cachexia.32
Despite differences in the site of tumour implantation,
gender, or mouse strain, most of the cachexia models that
are currently utilized for investigations in the ﬁeld (e.g. C26
or LLC) present similar phenotypes, although the molecular
mechanisms may differ signiﬁcantly. One of the advantages
of our animal model is that the intraperitoneal implantation
of ES-2 cells, recapitulating the clinical presentation of HGS-
OC (e.g. TP53 mutations, ascites formation, and hyper-
inﬂammatory state), also allows the study of the direct
muscle effects associated with the development of ovarian
tumours. Moreover, along with the fact that the ES-2 cells
exhibit moderate chemoresistance to a number of chemo-
therapeutic agents, including doxorubicin, cisplatin, and
etoposide,51 our model may also represent a suitable tool
for studies aimed at investigating the development of
chemoresistance and the occurrence of muscle toxicity that
follows to chemotherapy administration.24,49
Our data showed markedly elevated STAT3 phosphoryla-
tion in the skeletal muscle of ES-2 hosts and in myotubes ex-
posed to ES-2 CM. Interestingly, the levels of total STAT3
were also increased in the muscle of tumour hosts, in line
with our previous evidence reporting STAT3 itself among
the known STAT3 targets in cachectic muscles.14 Therefore,
our data suggest that muscle wasting in the presence of OC
may follow to activation of the IL-6/STAT3 signalling pathway,
in accordance with our previous ﬁndings.14,15 Indeed, the
manifestation of an overall inﬂammatory state is one of the
hallmarks of cachexia.57 In particular, the systemic metabolic
derangements that follow the occurrence of cancer cachexia
have been described in association with high levels of pro-
inﬂammatory cytokines, including tumor necrosis factor
(TNF), IL-1α, IL-1β, interferon-γ, and IL-6.58,14,59 Strong
evidence indicates that pro-inﬂammatory cytokines such as
IL-6 are markedly elevated in OC due to combined systemic
response to tumourigenesis and antineoplastic therapies. In
our animal model, making use of immune deﬁcient NSG mice,
markedly elevated human IL-6 levels were detected in plasma
and ascites. In a similar manner, high IL-6 was detected in ES-
2 abdominal tumours isolated from OC-bearers, therefore
suggesting that the ES-2 cells were the main source of this
cytokine. Of note, IL-6 in ascites was previously shown to
correlate with reduced survival as well as cachexia-related
symptoms (muscle depletion, increased fatigue, disability,
and depression) in OC patients.13,60 Moreover, published
studies suggest that pharmacologic inhibition of the IL-6 sig-
nalling both reduces OC growth and enhances the efﬁcacy
of chemo-therapy and radio-therapy,61,12,28,62 and also im-
proves muscle mass and restores muscle strength in
tumour-bearing mice.15 In line with these observations, here
we showed that pharmacologic inhibition of the IL-6/STAT3
signalling by means of INCB018424 was sufﬁcient to prevent
OC-induced myoﬁbre atrophy in C2C12 cultures.
Evidence from the literature supports the idea that mito-
chondrial alterations and enhanced protein catabolism are
among the most relevant factors associated with the develop-
ment of muscle atrophy in cancer. In our study, the levels of
regulators of mitochondrial fusion, such as OPA1 and
Mitofusin-2, and of mitochondrial biogenesis, such as PGC1α
and Cytochrome-C, were signiﬁcantly reduced in the muscle
of tumour hosts compared with the control animals. This sug-
gests that OC growth may affect the muscle mitochondrial
homoeostasis, thereby promoting metabolic derangements
that, in turn, could lead to occurrence of muscle atrophy and
increased fatigue. Our hypothesis was further supported by
the fact that, along with myoﬁbre atrophy, C2C12 myotubes
exposed to CM from ES-2 cells also showed modulation of mi-
tochondrial protein expression, reduced number of polarized
mitochondria, and abnormalities in mitochondrial respiration
and energy production. These ﬁndings are consistent with
our and other previous reports obtained by characterizing ex-
perimental models of cancer-induced or chemotherapy-
induced cachexia.24,63,15,64 Notably, White et al. suggested
that altered mitochondrial homoeostasis is an early event in
the initiation of IL-6 induced cachexia, which may precede
the loss of muscle mitochondria.65 Similarly, the ES-2 bearers
show the signs of markedly upregulated ubiquitin ligases ex-
pression, such as Atrgin-1, MuRF-2, and Fbxo31, and elevated
muscle protein ubiquitination, previously described as molec-
ular alterations consistent with cancer cachexia.43,66
In the present study, we also demonstrated that the over-
all body composition assessment by DXA was signiﬁcantly af-
fected in the ES-2 hosts, showing marked depletion of lean
and adipose tissue, as well as reduction in BMD and BMC.
These ﬁndings were consistent with the bone morphometry
analyses conducted by means of μCT scanning, reporting sig-
niﬁcant depletion of bone mass, along with reduced trabecu-
lar bone in both femurs and vertebrae. Ours is the ﬁrst report
showing involvement of bone tissue following growth of ex-
perimental OC. Although no functional measurements were
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performed on the bones from ES-2 hosts, our previous evi-
dence suggests that bone content generally correlates with
the overall bone strength in cancer cachexia.67 Although the
molecular mechanism(s) responsible for bone depletion in as-
sociation with the occurrence of OC are not known, high
levels of IL-6, as shown in the animals bearing the ES-2 OC,
have been previously reported in association not only with
the development of paraneoplastic complications, such as ca-
chexia, leucocytosis, and thrombocytosis, but also with the
occurrence of hypercalcaemia, a condition responsible for se-
vere loss of bone mass,68 or juvenile idiopathic arthritis, a sys-
temic inﬂammatory condition characterized by clinical
features that include stunted growth and skeletal abnormali-
ties.69,70 In this regard, elevated IL-6 seems to play a relevant
role by primarily affecting bone turnover, along with in-
creased bone resorption and reduced bone formation.71
Unlike our previous reports describing the occurrence of
bone loss following development of colorectal tumours or af-
ter prolonged administration of chemotherapy,48,67 bone tis-
sue is not generally investigated in the experimental models
utilized for the study of HGS-OCs. In the clinical setting, OC
is not frequently associated with enhanced bone fractures
per se or described as a risk factor for the development of os-
teoporosis, although elevated bone turnover markers were
detected in women undergoing risk-reducing salpingo-
oophorectomy to decrease the risk for breast cancer and
OC.72,73 Surgery represents the preferred treatment for OC
and frequently involves the removal of both ovaries as a part
of treatment, eventually followed by radiation therapy, intra-
peritoneal chemotherapy with platinum and a taxane, or hor-
mone replacement treatment.74 Consistently, women treated
for their gynaecologic cancers are often affected with
hypogonadism, along with reduced BMD as a consequence
of surgical or chemotherapy treatments.75–77 Indeed, bone
fragility represents a condition notoriously associated with
the occurrence of hypogonadism in a large percentage of pa-
tients and contributes to worsen the overall outcomes. While
in the present study we did not evaluate the presence of
bone tumours in the animals inoculated with ES-2 cells, the
formation of bone metastases is a rare, but well-recognized
event in OC, representing a factor predictive of poor progno-
sis and increased morbidity.78,79
In conclusion, we provided evidence that the growth of ES-
2 intraperitoneal xenografts causes progressive decline in
muscle weight and muscle function, depletion of adipose tis-
sue, and bone degeneration in association with high levels of
tumour-derived IL-6. In accordance with our previous ﬁnd-
ings, systemic inﬂammation, muscle protein hypercatabolism,
and mitochondrial alterations concur to the development of
cachexia. Overall, the in vivo implantation of ES-2 cells resem-
bles the clinical presentation of HGS-OCs and provides an ac-
curate in vivo platform for the study of OC-associated
cachexia and for future testing of targeted treatments. More-
over, our observations describe for the ﬁrst time the
occurrence of bone loss in association with OC and support
the importance of screening for bone quality in patients
receiving treatment for OC, especially in the long term.
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